Meeting
2016 ASCO Annual Meeting
Bendamustine for anaplastic gliomas.
Authors
Marc C. Chamberlain
University of Washington, Seattle, WA
Marc C. Chamberlain , Howard Colman , Jeffrey J. Raizer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00823797
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2051)
DOI
10.1200/JCO.2016.34.15_suppl.2051
Abstract #
2051
Poster Bd #
238
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors.
First Author: Yazmin Odia
Poster
2012 ASCO Annual Meeting
Phase II trial of sunitinib malate and lomustine in patients with temozolomide refractory recurrent low-grade and anaplastic gliomas.
First Author: Johnny Duerinck
Poster
2022 ASCO Annual Meeting
Phase 2 study to evaluate palbociclib in combination with irinotecan and temozolomide in pediatric patients with recurrent or refractory Ewing sarcoma.
First Author: Theodore Willis Laetsch
Poster
2020 ASCO Virtual Scientific Program
Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma.
First Author: Sylvia Christine Kurz